Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation safety study of IMO-2125 plus ribavirin in treatment-naïve genotype 1 hepatitis C
2009-011099-31Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- Apr 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tilsotolimod in hepatitis C virus infection (3 arms), sponsored by Aceragen, Inc. Primary endpoint: Safety and tolerability of IMO-2125 plus ribavirin. Started Apr 2010; status: completed.
02
Drugs
tilsotolimod
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-011099-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011099-31.